Polen Capital Management’s Alto Neuroscience ANRO Stock Holding History

Polen Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,613	Closed	-$373K	–	281
2026 Q1	$373K	Buy	+16,613	New	+$308K	﹤0.01%	193

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Polen Capital Management's ANRO Position: Q2 2026 in Review

Polen Capital Management sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 16,613 shares — an estimated $373K sold.

Polen Capital Management first reported a position in ANRO in Q1 2026 and held it in 1 quarter. The position peaked at $373K in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Polen Capital Management reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
Polen Capital Management sold 16,613 Alto Neuroscience shares in Q2 2026, an estimated $373K.
Polen Capital Management first reported a position in Alto Neuroscience in Q1 2026 and held it in 1 quarter.
Polen Capital Management's Alto Neuroscience position peaked at $373K in Q1 2026.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Polen Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.